UNSPSC 51372402: Proheptazine

This classification denotes an analgesic agent with the molecular formula C17H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S23189WW7E, chemically known as 1,3-dimethyl-4-phenyl-4-propionyloxyazacycloheptane but generally known as proheptazine, which bears US NIH Compound Identifier 60969. European Medicines Agency schedules Proheptazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10080MIG. The term PROHEPTAZINE is an International Non-Proprietary Name.

UNSPSC 51372402 Proheptazine is a Commodity code that in practice captures state and local procurement of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products supplied through established wholesale channels and direct-to-manufacturer arrangements. State and local governments buy these items to support community health and emergency response initiatives, pharmacy benefit programs for employees and retirees, and public health facilities. The issuing bodies soliciting under this code span county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that aggregate demand across participating jurisdictions and agencies.

Recent activity shows three representative solicitations across different geographies and procurement approaches. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building; the contract carries a two-year initial term with a one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling state interest in alternative fulfillment models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers with proposals due March 26, 2026; MMCAP sourcing extends to participating jurisdictions including Oregon. Activity appears concentrated in the upper Midwest and Southeast, with multi-state cooperative purchasing vehicles serving as key aggregation mechanisms for pharmaceutical procurement.